2.50
Hdl Handle:
http://hdl.handle.net/10541/74818
Title:
Anti-CD 40 monoclonal antibody.
Authors:
Geldart, Tom; Illidge, Timothy M ( 0000-0003-3191-7324 )
Abstract:
Normal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.
Affiliation:
Cancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.
Citation:
Anti-CD 40 monoclonal antibody. 2005, 46 (8):1105-13 Leuk. Lymphoma
Journal:
Leukemia & Lymphoma
Issue Date:
Aug-2005
URI:
http://hdl.handle.net/10541/74818
DOI:
10.1080/10428190500085255
PubMed ID:
16085550
Type:
Article
Language:
en
ISSN:
1042-8194
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGeldart, Tom-
dc.contributor.authorIllidge, Timothy M-
dc.date.accessioned2009-07-21T16:40:04Z-
dc.date.available2009-07-21T16:40:04Z-
dc.date.issued2005-08-
dc.identifier.citationAnti-CD 40 monoclonal antibody. 2005, 46 (8):1105-13 Leuk. Lymphomaen
dc.identifier.issn1042-8194-
dc.identifier.pmid16085550-
dc.identifier.doi10.1080/10428190500085255-
dc.identifier.urihttp://hdl.handle.net/10541/74818-
dc.description.abstractNormal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntigens, CD40-
dc.subject.meshCD40 Ligand-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy-
dc.subject.meshLigands-
dc.subject.meshModels, Immunological-
dc.subject.meshNeoplasms-
dc.subject.meshSignal Transduction-
dc.titleAnti-CD 40 monoclonal antibody.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.en
dc.identifier.journalLeukemia & Lymphomaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.